SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Boysen Gudrun))
 

Search: (WFRF:(Boysen Gudrun)) > Angiotensin recepto...

  • Sandset, Else Charlotte (author)

Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial : rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003)

  • Article/chapterEnglish2010

Publisher, publication year, extent ...

  • 2010-09-02
  • SAGE Publications,2010
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-135011
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-135011URI
  • https://doi.org/10.1111/j.1747-4949.2010.00473.xDOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background Elevated blood pressure following acute stroke is common, and yet early antihypertensive treatment is controversial. ACCESS suggested a beneficial effect of the angiotensin receptor blocker candesartan in the acute phase of stroke, but these findings need to be confirmed in new, large trials. Aims and design The Scandinavian Candesartan Acute Stroke Trial is an international randomised, placebo-controlled, double-blind trial of candesartan in acute stroke. We plan to recruit 2500 patients presenting within 30 h of stroke (ischaemic or haemorrhagic) and with systolic blood pressure >= 140 mmHg. The recruited patients are randomly assigned to candesartan or placebo for 7-days (doses increasing from 4 to 16 mg once daily). Randomisation is performed centrally via a secure web interface. The follow-up period is 6-months. Patients are included from the following nine North-European countries: Norway, Sweden, Denmark, Belgium, Germany, Poland, Lithuania, Estonia and Finland. Study outcomes There are two co-primary effect variables:center dot Functional status at 6-months, measured by the modified Rankin Scale, and center dot vascular death, myocardial infarction or stroke during the first 6-months.Secondary outcome variables:Secondary effect variables include center dot the Barthel index (functional status)center dot EuroQol (quality of life) and center dot Mini-mental state examination (cognition) at 6-months center dot Health economic costs during the first 6-months Funding The Scandinavian Candesartan Acute Stroke Trial receives basic funding from Norwegian health authorities. AstraZeneca supplies the trial drugs, and AstraZeneca and Takeda support the trial with limited, unrestricted grants. Summary The Scandinavian Candesartan Acute Stroke Trial is the first large trial of angiotensin receptor blockers in patients with elevated blood pressure and acute stroke, and aims to answer whether treatment with angiotensin receptor blockers is beneficial for this indication.

Subject headings and genre

  • acute stroke
  • angiotensin receptors blockers
  • antihypertensive therapy
  • candesartan
  • randomised-controlled trial
  • MEDICINE
  • MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

  • Murray, Gordon (author)
  • Boysen, Gudrun (author)
  • Jatuzis, Dalius (author)
  • Kõrv, Janika (author)
  • Lueders, Stephan (author)
  • Richter, Przemyslaw S. (author)
  • Roine, Risto O. (author)
  • Terént, AndreasUppsala universitet,Institutionen för medicinska vetenskaper(Swepub:uu)andrtere (author)
  • Thijs, Vincent (author)
  • Berge, Eivind (author)
  • Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Related titles

  • In:International Journal of Stroke: SAGE Publications5:5, s. 423-4271747-49301747-4949

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view